Get the Stockscreener App
32.97
1.79%
-0.60
Capricor Therapeutics Inc stock is traded at $32.97, with a volume of 387.24K.
It is down -1.79% in the last 24 hours and up +39.29% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$33.57
Open:
$33.94
24h Volume:
387.24K
Relative Volume:
0.27
Market Cap:
$1.79B
Revenue:
$11.13M
Net Income/Loss:
$-81.99M
P/E Ratio:
-18.33
EPS:
-1.7988
Net Cash Flow:
$-68.38M
1W Performance:
+27.69%
1M Performance:
+39.29%
6M Performance:
+418.40%
1Y Performance:
+152.26%
1-Day Range:
$32.25
$34.21
1-Week Range:
$25.08
$36.49
52-Week Range:
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
32.94 | 1.83B | 11.13M | -81.99M | -68.38M | -1.7988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.77 | 125.08B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.77 | 81.90B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
709.49 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.59 | 42.50B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
287.51 | 33.16B | 5.36B | 287.73M | 924.18M | 2.5229 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | Alliance Global Partners | Buy |
| Jun-26-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | Roth Capital | Buy |
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
Capricor Therapeutics (CAPR) Reveals Promising Data from Phase 3 HOPE-3 Trial - GuruFocus
Capricor earnings on deck after FDA resumes deramiocel review By Investing.com - Investing.com Nigeria
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data - GlobeNewswire
Capricor Therapeutics Hits Day High with 8.06% Surge in Stock Price - Markets Mojo
Capricor Therapeutics (CAPR) Set to Announce Q4 Earnings - GuruFocus
Capricor Therapeutics Hits Day High with Strong 9.04% Intraday Surge - Markets Mojo
FDA resumes review of Capricor’s cell therapy deramiocel - The Pharma Letter
Capricor Therapeutics Hits Day High with Strong 9.78% Intraday Surge - Markets Mojo
Capricor Therapeutics Opens with 10.29% Gain, Outperforming S&P 500's 0.83% Rise - Markets Mojo
FDA resumes review of Capricor’s Deramiocel for DMD treatment By Investing.com - Investing.com Canada
Capricor Therapeutics (CAPR) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
H.C. Wainwright Maintains Buy on Capricor Therapeutics, Inc. (CAPR) Mar 2026 - Meyka
Why Capricor Therapeutics (CAPR) Is Up 29.3% After FDA Resumes Review of Deramiocel BLA - simplywall.st
Capricor Therapeutics (CAPR) Surges as FDA Reviews Key Therapy - GuruFocus
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? - Sahm
Capricor Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
CAPR Stock Surged 17% Today — What’s Fueling The Rally? - Stocktwits
Capricor Therapeutics Rises as FDA Lifts Complete Response Letter, Resumes Review - marketscreener.com
Capricor Therapeutics Sees Surge in Trading Volume - National Today
Capricor Therapeutics (NASDAQ:CAPR) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Jones Trading reiterates Capricor stock Buy on FDA review resumption By Investing.com - Investing.com Canada
HC Wainwright Reiterates Buy Rating for Capricor Therapeutics (C - GuruFocus
Capricor Advances Deramiocel BLA Review for Duchenne DMD - TipRanks
Capricor Therapeutics stock surges on FDA BLA review resumption - Investing.com
Capricor Therapeutics (NASDAQ:CAPR) Given "Buy" Rating at HC Wainwright - MarketBeat
Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Benzinga
Capricor resumes FDA BLA review for Deramiocel; PDUFA date set for Aug 22, 2026 - TradingView
FDA sets new Deramiocel PDUFA date for Capricor (NASDAQ: CAPR) - Stock Titan
Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review - Benzinga
FDA Resumes Review of Capricor Therapeutics' (CAPR) Deramiocel A - GuruFocus
Capricorgains FDA reviews rejected cell therapy (CAPR:NASDAQ) - Seeking Alpha
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA - Bitget
Capricor Therapeutics, Inc. resumes Deramiocel BLA review as FDA sets August 22, 2026 deadline - Traders Union
Capricor Therapeutics Announces Resumption of FDA BLA Review for Deramiocel in Duchenne Muscular Dystrophy Following Positive Phase 3 Results - Quiver Quantitative
FDA resumes review of Duchenne drug Deramiocel, sets Aug. 22 deadline - Stock Titan
Xenon hits a ‘home run’ in epilepsy; FDA restarts review of Duchenne cell therapy - Yahoo Finance
Biotech Stocks Pop After CBER Chief ExitModerna (NASDAQ:MRNA) - Benzinga
Capricor Therapeutics (NASDAQ:CAPR) Shares Gap UpStill a Buy? - MarketBeat
Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds - TechStock²
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12 - The Manila Times
Capricor Therapeutics to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 - Quiver Quantitative
A Look At Capricor Therapeutics (CAPR) Valuation As FDA Tightens Expedited Approval Pathway - Sahm
Capricor Therapeutics Stock Pre-Market (+12%): 91-Day Insider Lock-Up Period Expires - Trefis
CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains - Stocktwits
Capricor Therapeutics Poised for Breakthrough as HOPE-3 Trial Results Loom - timothysykes.com
Capricor Therapeutics (NASDAQ:CAPR) Trading Up 6.2%Here's What Happened - MarketBeat
Capricor Therapeutics Stock Jumps After-Hours As Retail Cheers Fresh FDA Attempt After Duchenne Therapy Rejection - Stocktwits
HOPE On The Horizon: Capricor To Present Deramiocel Data At The MDA Conference - RTTNews
CAPR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Capricor (CAPR) Faces Challenges Amidst Stricter FDA Approval Pr - GuruFocus
Register: Aligning With the FDA on a Regulatory Pathway To Avoid Decision Day Surprises - BioSpace
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):